Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations
Substance use disorder (SUD) affects millions globally, often impairing brain reward circuits and personal life. Treatments face challenges like limited availability and poor patient retention. A non-systematic review of studies published through December 2021 examined classic (LSD, DMT, psilocybin, mescaline) and non-classic (ibogaine, ketamine, MDMA, salvinorin A, THC) psychedelics for SUD. Results are inconclusive for LSD, DMT, mescaline, MDMA, and salvinorin A. Moderate evidence supports psilocybin and ketamine for alcohol use disorder, ketamine for opiate and alcohol withdrawal, and THC preparations for reducing withdrawal in cannabis and possibly opioid use disorder. Psychedelics appear more effective as adjunct therapy. More research is needed.